Please provide your email address to receive an email when new articles are posted on . 87.3% of white patients and 92.8% of Black patients had no severe exacerbations with omalizumab. 4% of white ...

The digital press release with multimedia content can be accessed here: Basel, June 3, 2019 - Novartis today announced positive topline data from two phase III, multicenter studies evaluating ...

JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO ® (omalizumab-igec) as the first and only biosimilar designated ...

Please provide your email address to receive an email when new articles are posted on . The percentage of patients experiencing chest pain exacerbations fell from 6% to 0%. Daily inhaled ...

Objectives: To describe allergic asthma and allergic rhinitis pathophysiology and review the pharmacologic, pharmacokinetic, pharmacodynamic, efficacy, and safety data for omalizumab. Methods: MEDLINE ...

Peter L. Salgo, MD: Let’s discuss omalizumab. Now that’s FDA approved. Don A. Bukstein, MD: Yeah. Omalizumab was the first; it’s been around. Peter L. Salgo, MD: And what is the indication for it? Don ...

Findings showed equivalent efficacy in change from baseline in weekly itch severity score between omalizumab-igec 300mg and Xolair 300mg. The Food and Drug Administration (FDA) has approved Omlyclo ® ...

A major breakthrough in protection against severe allergies could have been made after a study found an asthma drug to increase allergen tolerance. The study by The New England Journal of Medicine ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of omalizumab, having considered evidence on the nature of chronic spontaneous urticaria and the value placed ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory condition in the U.S., drugmaker Celltrion announced Monday. The ...

This is a case study of a male patient with Fabry disease who presented with severe anaphylaxis following re-initiation of full-strength treatment with intravenous agalsidase beta (Fabrazyme). A ...

Findings showed 67% of the omalizumab group achieved the primary endpoint compared with 7% of the placebo group. Treatment with omalizumab, an anti-IgE antibody, significantly increased the amount of ...